Adenovirus vaccine immunotherapy targeting WT1-expressing tumors

Expert Opinion on Biological Therapy

Volumn 10, Issue 6, 2010, Pages 875-883

  Clarke, Jeffrey M ^a   Morse, Michael A ^b   Lyerly, H Kim ^c   Clay, Timothy ^d   Osada, Tayuka ^e  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Medical Center   (United States)

Author keywords

Adenovirus; Cancer; Immunotherapy; Vaccine; Wilm's tumor gene; WT1

Indexed keywords

ADENOVIRUS VECTOR; BCG VACCINE; CANCER VACCINE; CD86 ANTIGEN; CONDITIONALLY REPLICATING ADENOVIRUS; DENDRITIC CELL VACCINE; DNA VACCINE; GLYCOPROTEIN GP 100; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RESTRICTED PEPTIDE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; PEPTIDE VACCINE; PLACEBO; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE; WT1 PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DESIGN; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; GENE OVEREXPRESSION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; KIDNEY CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROSTATE CANCER; REVIEW; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS AS TOPIC; GENES, WILMS TUMOR; HUMANS; NEOPLASMS; VIRAL VACCINES;

ADENOVIRIDAE;

EID: 77952209021     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712591003798278     Document Type: Review

References (75)

1. Park JM, Terabe M, Sakai Y, et al. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005;10(7):4228-4236
2. Park JM, Terabe M, Steel JC, et al. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res 2008;68(6):1979-1987
3. Gjertsen MK, Bjorheim J, Saeterdal I, et al. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72(5):784-790
4. Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998;188(12):2357-2368
5. Osada T, Woo CY, McKinney M, et al. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res 2009;15(8):2789-2796 •• The first reported use, to our knowledge, of Ad-WT1 for vaccine immunotherapy in vivo.
6. Rauscher FJ III, Morris JF, Tournay OE, et al. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990;250(4985):1259-1262
7. Drummond IA, Madden SL, Rohwer-Nutter P, et al. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992;257(5070):674-678
8. Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 1993;90(12):5828-5832
9. Harrington MA, Konicek B, Song A, et al. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993;268(28):21271-21275
10. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990;346(6280):194-197
11. Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14(19):4662-4675
12. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001;273(2):141-161
13. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60(3):509-520
14. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90(2):194-204
15. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6(5):405-409
16. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90(3):1217-1225
17. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, et al. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 2006;6:90
18. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8(5):1167-1171 (Pubitemid 34517654)
19. Sera T, Hiasa Y, Mashiba T, et al. Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer 2008;44(4):600-608
20. Oka Y, Tsuboi A, Oji Y, et al. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008;20(2):211-220
21. Hutchings Y, Osada T, Woo CY, et al. Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther 2007;9(1):62-69
22. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000;51(2):99-107 (Pubitemid 30150969)
23. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95(7):2198-2203
24. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95(1):286-293
25. Al Qudaihi G, Lehe C, Negash M, et al. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue. Leuk Lymphoma 2009;50(2):260-269
26. Pinilla-Ibarz J, May RJ, Korontsvit T, et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006;20(11):2025-2033
27. Guo Y, Niiya H, Azuma T, et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood 2005;106(4):1415-1418
28. Kobayashi H, Nagato T, Aoki N, et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006;55(7):850-860
29. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99(9):3272-3279
30. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 2000;164(4):1873-1880 • One of the first reports detailing WT1 immunotherapy in vivo for WT1 expressing tumors.
31. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000;96(4):1480-1489
32. Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000;20(3):195-202 (Pubitemid 30485880)
33. Nakajima H, Kawasaki K, Oka Y, et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 2004;53(7):617-624
34. Chaise C, Buchan SL, Rice J, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008;112(7):2956-2964
35. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)- specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101(38):13885-13890 • The first major, Phase I clinical trial, to our knowledge, evaluating WT1 peptide based vaccine in patients with both hematological and solid malignancies.
36. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111(1):236-242
37. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113(26):6541-6548
38. Morita S, Oka Y, Tsuboi A, et al. A Phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 2006;36(4):231-236
39. Iiyama T, Udaka K, Takeda S, et al. WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007;51(5):519-530
40. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008;108(5):963-971
41. Woo CY, Osada T, Clay TM, et al. Recent clinical progress in virus-based therapies for cancer. Expert Opin Biol Ther 2006;6(11):1123-1134
42. Vujanovic L, Whiteside TL, Potter DM, et al. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother 2009;58(1):121-133
43. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998;91(2):392-398
44. Juillard V, Villefroy P, Godfrin D, et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur J Immunol 1995;25(12):3467-3473
45. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996;2(5):545-550
46. Gallo P, Dharmapuri S, Cipriani B, Monaci P. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther 2005;12(Suppl 1):S84-91
47. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008;25(4):462-466
48. Seregin SS, Amalfitano A. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin Biol Ther 2009;9(12):1521-1531
49. Harui A, Suzuki S, Kochanek S, Mitani K. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 1999;73(7):6141-6146
50. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372(9653):1881-1893
51. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91(10):4407-4411
52. Bachtarzi H, Stevenson M, Fisher K. Cancer gene therapy with targeted adenoviruses. Expert Opin Drug Deliv 2008;5(11):1231-1240
53. Osada T, Yang XY, Hartman ZC, et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009;16(9):673-682
54. Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 2006;16(3):241-259
55. Gallo P, Dharmapuri S, Nuzzo M, et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005;113(1):67-77
56. Chan T, Sami A, El-Gayed A, et al. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther 2006;13(19):1391-1402
57. Morse MA, Wei J, Hartman Z, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer 2009 [Epub Ahead of Print]
58. Essand M. Gene therapy and immunotherapy of prostate cancer: adenoviral-based strategies. Acta Oncol 2005;44(6):610-627
59. Elzey BD, Siemens DR, Ratliff TL, Lubaroff DM. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001;94(6):842-849
60. Kim S, Lee JB, Lee GK, Chang J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 2009;69(9):938-948
61. Lane C, Leitch J, Tan X, et al. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 2004;64(4):1509-1514
62. Leitch J, Fraser K, Lane C, et al. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J Immunol 2004;172(9):5200-5205
63. Steitz J, Bruck J, Knop J, Tuting T. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism. Gene Ther 2001;8(16):1255-1263
64. Wan Y, Bramson J, Pilon A, et al. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Cancer Res 2000;60(12):3247-3253
65. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90(24):1894-1900
66. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur Urol 2000;38(2):208-217
67. Nemunaitis J, Meyers T, Senzer N, et al. Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther 2006;13(6):1185-1191
68. Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31(3):294-309
69. Bardeesy N, Pelletier J. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. Nucleic Acids Res 1998;26(7):1784-1792
70. Kast WM, Levitsky H, Marincola FM. Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy. J Transl Med 2004;2(1):20
71. Oh ST, Kim CH, Park MY, et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006;24(15):2860-2868
72. Lehe C, Ghebeh H, Al-Sulaiman A, et al. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res 2008;68(15):6350-6359
73. Salucci V, Mennuni C, Calvaruso F, et al. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand. Scand J Immunol 2006;63(1):35-41
74. Thacker EE, Nakayama M, Smith BF, et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009;27(50):7116-7124
75. Kline J. Will changing the face of WT1 make it more attractive to T cells? Leuk Lymphoma 2009;50(2):156-157